The acquisition of Dorland Global Corporation extends the reach of Huntsworth Health into the lucrative US market.
Huntsworth will pay an initial £10.3m in cash for Dorland, whose clients include Novartis and Procter & Gamble. The final amount could rise depending on its performance between now and 2010.
Huntsworth CEO Lord Chadlington said: ‘It has always been our ambition to add a US arm to our highly successful UK healthcare group, which together with our European presence gives our healthcare business a truly global reach.'
Harry Sweeney, chairman and CEO of Dorland, said the deal had been prompted by ‘the shift in the pharmaceutical sector towards globalisation and the growth of e-marketing'.